Superworth

Century Therapeutics profit margin IPSC

Gross, operating and net profit as a share of revenue over the last twelve months, from 2025.

Net margin, 12 months
n/m
a quarter missing
Peer median
21.7%

Century Therapeutics' net margin over the last twelve months can't be worked out yet: a quarter of its results is missing from our data.

Profit margin over time

OperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating margin
FY2025−8.8%−15.8%
FY2024n/an/a
FY2023n/an/a
FY2022n/an/a
FY2021n/an/a
FY2020n/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY26n/an/an/a
Q1 FY26n/an/an/a
Q4 FY25−8.8%n/a−15.8%
Q3 FY25−23.4%n/a−29.9%
Q2 FY25−20.4%n/a−28.5%
Q1 FY25−19.1%n/a−28.4%
Q4 FY24n/an/an/a
Q3 FY24n/an/an/a
Q2 FY24n/an/an/a
Q1 FY24n/an/an/a
Q4 FY23n/an/an/a
Q3 FY23n/an/an/a

Against its peers

Companies in Biotechnology nearest Century Therapeutics' size, closest first, today.

CompanyProfit margin
IPSCCentury Therapeuticsn/m
PLXProtalix BioTherapeutics23.5%
MGTXMeiraGTx19.9%
VCELVericel7.9%
ADMAAdma Biologics33.0%
Peer median21.7%

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Century Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.